Xilio Therapeutics (XLO) Total Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics (XLO) has 6 years of Total Non-Current Liabilities data on file, last reported at $64.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $64.7 million; the trailing twelve-month figure through Mar 2026 stood at $64.7 million (changed N/A YoY), and the FY2025 full-year result was $89.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities retreated to $64.7 million in Q1 2026, from $89.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $89.9 million in Q4 2025 to a low of $25.0 million in Q2 2023.
• A 4-year average of $51.1 million and a median of $33.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities increased 2.95% in 2022 and dropped 26.17% in 2023, its largest moves.
• Tracing XLO's Total Non-Current Liabilities over 4 years: stood at $33.5 million in 2022, then declined by 25.39% to $25.0 million in 2023, then surged by 259.77% to $89.9 million in 2025, then dropped by 28.01% to $64.7 million in 2026.
• Business Quant data shows XLO's Total Non-Current Liabilities at $64.7 million in Q1 2026, $89.9 million in Q4 2025, and $87.9 million in Q3 2025.